{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T17:48:20Z","timestamp":1789321700984,"version":"build-2803163510"},"reference-count":35,"publisher":"American Society for Microbiology","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin. Vaccine Immunol."],"published-print":{"date-parts":[[2015,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>In 2009, a global epidemic of influenza A(H1N1) virus caused the death of tens of thousands of people. Vaccination is the most effective means of controlling an epidemic of influenza and reducing the mortality rate. In this study, the long-term immunogenicity of influenza A\/California\/7\/2009 (H1N1) split vaccine was observed as long as 15 months (450 days) after immunization in a mouse model. Female BALB\/c mice were immunized intraperitoneally with different doses of aluminum-adjuvanted vaccine. The mice were challenged with a lethal dose (10\u00d7 50% lethal dose [LD<jats:sub>50<\/jats:sub>]) of homologous virus 450 days after immunization. The results showed that the supplemented aluminum adjuvant not only effectively enhanced the protective effect of the vaccine but also reduced the immunizing dose of the vaccine. In addition, the aluminum adjuvant enhanced the IgG antibody level of mice immunized with the H1N1 split vaccine. The IgG level was correlated to the survival rate of the mice. Aluminum-adjuvanted inactivated split-virion 2009 pandemic influenza A H1N1 vaccine has good immunogenicity and provided long-term protection against lethal influenza virus challenge in mice.<\/jats:p>","DOI":"10.1128\/cvi.00662-14","type":"journal-article","created":{"date-parts":[[2015,1,15]],"date-time":"2015-01-15T06:36:36Z","timestamp":1421303796000},"page":"327-335","source":"Crossref","is-referenced-by-count":9,"title":["Long-Term Immunogenicity of an Inactivated Split-Virion 2009 Pandemic Influenza A H1N1 Virus Vaccine with or without Aluminum Adjuvant in Mice"],"prefix":"10.1128","volume":"22","author":[{"given":"Wenting","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","published-online":{"date-parts":[[2015,1,14]]},"reference":[{"key":"key20180919073758_B1","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/nature08182","article-title":"Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic","volume":"459","year":"2009","journal-title":"Nature"},{"key":"key20180919073758_B2","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1002\/eji.200939911","article-title":"A novel H1N1 virus causes the first pandemic of the 21st century","volume":"39","year":"2009","journal-title":"Eur J Immunol"},{"key":"key20180919073758_B3","volume-title":"Pandemic (H1N1) 2009\u2014update 112","author":"World Health Organization","year":"2009"},{"key":"key20180919073758_B4","volume-title":"CDC estimate of global H1N1 pandemic deaths: 284,000","year":"2012"},{"key":"key20180919073758_B5","doi-asserted-by":"publisher","first-page":"4895","DOI":"10.1016\/j.vaccine.2010.05.031","article-title":"The 2009 A(H1N1) influenza virus pandemic: a review","volume":"28","year":"2010","journal-title":"Vaccine"},{"key":"key20180919073758_B6","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1086\/649428","article-title":"A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1","volume":"201","year":"2010","journal-title":"J Infect Dis"},{"key":"key20180919073758_B7","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1056\/NEJMoa0907413","article-title":"Response to a monovalent 2009 influenza A(H1N1) vaccine","volume":"361","year":"2009","journal-title":"N Engl J Med"},{"key":"key20180919073758_B8","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1056\/NEJMoa0908535","article-title":"A novel influenza A(H1N1) vaccine in various age groups","volume":"361","year":"2009","journal-title":"N Engl J Med"},{"key":"key20180919073758_B9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0140-6736(09)62026-2","article-title":"Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials","volume":"375","year":"2010","journal-title":"Lancet"},{"key":"key20180919073758_B10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0140-6736(09)62039-0","article-title":"Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial","volume":"375","year":"2010","journal-title":"Lancet"},{"key":"key20180919073758_B11","volume-title":"Pandemic influenza vaccine clinical trial abstract minimum information: summary on H1N1 vaccine in China: state manufacturers","year":"2009"},{"key":"key20180919073758_B12","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1086\/656601","article-title":"A single dose of unadjuvanted novel 2009 H1N1 vaccine is immunogenic and well tolerated in young and elderly adults","volume":"202","year":"2010","journal-title":"J Infect Dis"},{"key":"key20180919073758_B13","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.rinim.2012.10.001","article-title":"The long-term immunogenicity of an inactivated split-virion 2009 pandemic influenza A H1N1 vaccine: randomized, observer-masked, single-center clinical study","volume":"2","year":"2012","journal-title":"Results Immunol"},{"issue":"1","key":"key20180919073758_B14","doi-asserted-by":"publisher","first-page":"e54334","DOI":"10.1371\/journal.pone.0054334","article-title":"NA proteins of influenza A viruses H1N1\/2009, H5N1, and H9N2 show differential effects on infection initiation, virus release, and cell-cell fusion","volume":"8","year":"2013","journal-title":"PLoS One"},{"key":"key20180919073758_B15","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00705-013-1852-y","article-title":"Evaluation of neutralizing efficacy of monoclonal antibodies specific for 2009 pandemic H1N1 influenza A virus in vitro and in vivo","volume":"159","year":"2014","journal-title":"Arch Virol"},{"key":"key20180919073758_B16","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00705-013-1878-1","article-title":"Comparative analysis of antibody induction and protection against influenza virus infection by DNA immunization with HA, HAe, and HA1 in mice","volume":"159","year":"2014","journal-title":"Arch Virol"},{"key":"key20180919073758_B17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.bbrc.2005.01.109","article-title":"Protection of inactivated influenza virus vaccine against lethal influenza virus infection in diabetic mice","volume":"329","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"key20180919073758_B18","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/1471-2334-7-118","article-title":"Vaccination with hemagglutinin or neuraminidase DNA protects BALB\/c mice against influenza virus infection in presence of maternal antibody","volume":"7","year":"2007","journal-title":"BMC Infect Dis"},{"key":"key20180919073758_B19","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1089\/dna.2005.24.758","article-title":"Maternal immunization with both hemagglutinin- and neuraminidase-expressing DNAs provides an enhanced protection against a lethal influenza virus challenge in infant and adult mice","volume":"24","year":"2005","journal-title":"DNA Cell Biol"},{"key":"key20180919073758_B20","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1128\/JVI.06034-11","article-title":"Elicitation of anti-1918 influenza virus immunity early in life prevents morbidity and lower levels of lung infection by 2009 pandemic H1N1 influenza virus in aged mice","volume":"86","year":"2012","journal-title":"J Virol"},{"issue":"11","key":"key20180919073758_B21","doi-asserted-by":"publisher","first-page":"e80762","DOI":"10.1371\/journal.pone.0080762","article-title":"Protective efficacy of a human endogenous retrovirus envelope-coated, nonreplicable, baculovirus-based hemagglutin vaccine against pandemic influenza H1N1 2009","volume":"8","year":"2013","journal-title":"PLoS One"},{"key":"key20180919073758_B22","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.vaccine.2012.12.072","article-title":"Cold-adapted X-31 live attenuated 2009 pandemic H1N1 influenza vaccine elicits protective immune responses in mice and ferrets","volume":"31","year":"2013","journal-title":"Vaccine"},{"key":"key20180919073758_B23","doi-asserted-by":"publisher","first-page":"5271","DOI":"10.4049\/jimmunol.178.8.5271","article-title":"Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release","volume":"178","year":"2007","journal-title":"J Immunol"},{"key":"key20180919073758_B24","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1084\/jem.20071087","article-title":"Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells","volume":"205","year":"2008","journal-title":"J Exp Med"},{"issue":"12","key":"key20180919073758_B25","doi-asserted-by":"publisher","first-page":"e29008","DOI":"10.1371\/journal.pone.0029008","article-title":"Long-lasting immune responses 4 years after GAD-alum treatment in children with type 1 diabetes","volume":"6","year":"2011","journal-title":"PLoS One"},{"key":"key20180919073758_B26","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.4049\/jimmunol.1002881","article-title":"A unique role of the cholera toxin A1-DD adjuvant for long-term plasma and memory B cell development","volume":"186","year":"2011","journal-title":"J Immunol"},{"key":"key20180919073758_B27","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1126\/science.1089926","article-title":"Promotion of B cell immune responses via an alum-induced myeloid cell population","volume":"304","year":"2004","journal-title":"Science"},{"key":"key20180919073758_B28","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1586\/erv.10.111","article-title":"MF59 as a vaccine adjuvant: a review of safety and immunogenicity","volume":"9","year":"2010","journal-title":"Expert Rev Vaccines"},{"key":"key20180919073758_B29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1586\/erv.12.140","article-title":"The history of MF59 adjuvant: a phoenix that arose from the ashes","volume":"12","year":"2013","journal-title":"Expert Rev Vaccines"},{"issue":"12","key":"key20180919073758_B30","doi-asserted-by":"publisher","first-page":"e4028","DOI":"10.1371\/journal.pone.0004028","article-title":"Safety, humoral and cell mediated immune responses to two formulations of an inactivated, split-virion influenza A\/H5N1 vaccine in children","volume":"3","year":"2008","journal-title":"PLoS One"},{"key":"key20180919073758_B31","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1016\/j.vaccine.2010.01.044","article-title":"Production of H5N1 (NIBRG-14) inactivated whole virus and split virion influenza vaccines and analysis of immunogenicity in mice using different adjuvant formulations","volume":"28","year":"2010","journal-title":"Vaccine"},{"key":"key20180919073758_B32","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1097\/INF.0b013e31824b9545","article-title":"Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A\/H1N1 influenza vaccine in children 3 to < 9 years of age","volume":"31","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"key20180919073758_B33","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1056\/NEJMoa0907650","article-title":"Trial of 2009 influenza A(H1N1) monovalent MF59-adjuvanted vaccine","volume":"361","year":"2009","journal-title":"N Engl J Med"},{"key":"key20180919073758_B34","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1086\/527489","article-title":"Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults","volume":"197","year":"2008","journal-title":"J Infect Dis"},{"key":"key20180919073758_B35","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/S0140-6736(06)69294-5","article-title":"Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A(H5N1) vaccine: a phase I randomised controlled trial","volume":"368","year":"2006","journal-title":"Lancet"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1128\/CVI.00662-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:51:22Z","timestamp":1627591882000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00662-14"}},"subtitle":[],"editor":[{"given":"R. L.","family":"Hodinka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,1,14]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,2,25]]},"published-print":{"date-parts":[[2015,3]]}},"alternative-id":["10.1128\/CVI.00662-14"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00662-14","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,14]]}}}